Clinical Trials Browser

Smoking Cessation, Neoplasms, Second Primary, Behavior, Addictive

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

57 enrolled

Tumor-Agnostic

Neoplasms, Second Primary

NCT05664009 2024-04-05

The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults

Phase 2 Recruiting

72 enrolled

Fatigue, Neoplasms, Second Primary

NCT02530515 2019-10-29

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

8 enrolled 6 charts

Classical hematologyLymphoidOther hematologic neoplasm

Lymphadenopathy, Anemia, Communicable Diseases, Fever, Lymphocytosis, Thrombocytopenia, Weight Loss, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Neoplasms, Second Primary

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Phase 2 Not yet recruiting

120 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasms, Second Primary

NCT00638963 2017-06-14

STOP

Phase 2 Terminated

6 enrolled 9 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasms, Second Primary

NCT00400426 2013-06-19

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

Phase 2 Completed

100 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence, Neoplasms, Second Primary

Clinical Trials

TTOP

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

STOP

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer